查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092501

口腔黏膜炎：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

Global Oral Mucositis - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 156 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 德國口腔黏膜炎市場預計將從2025年的5,500萬美元成長到2035年的1.3億美元。
  • 推動市場成長的因素如下：
  • 癌症發生率上升和強化抗癌療法的使用增加
  • 擴大支持性護理和新型預防療法的引進
  • 未來的成長取決於能夠預防嚴重黏膜炎和改善治療連續性的治療方法。

口腔粘膜炎概述

口腔黏膜炎是一種疼痛且常伴隨功能障礙的口腔黏膜損傷，通常由化療、放射線治療和幹細胞移植引起。這種情況往往需要中斷或減低原有的癌症治療，顯著影響患者的營養狀況、身心健康和生活品質。儘管數十年來臨床上對此進行了廣泛關注，但目前仍無根治性療法可以預防或治癒該疾病，且該領域的藥物研發難以將早期有前景的研究成果轉化為獲批上市的產品。因此，口腔衛生方案、冷卻療法、保護性塗層和光生物調節等支持性療法已成為治療的實用基礎。目前，研究重點正轉向影響病情嚴重程度的生物學因素，特別是口腔微生物群在加劇組織損傷中的作用，並探索新的研究方法，以期開發將抗炎和抗菌作用與組織修復機制相結合的聯合治療策略，而非僅僅針對單一因素。對於相關人員，口腔黏膜炎仍然是一個需要持續支持性治療的領域，儘管缺乏有效的治療方法，但不斷成長的治療需求仍然存在。

主要亮點

  • 根據預測，德國新確診的口腔黏膜炎病例數將從2025年的562,562 例增加到2035年的602,105 例。
  • 口腔粘膜炎是化療和放射線治療常見的併發症，嚴重影響患者的生活品質和治療順從性。
  • 在嚴重的情況下，這會導致治療中斷、感染風險增加和醫療保健成本飆升。
  • 目前，對於預防和治療口腔黏膜損傷的有效療法仍存在巨大的未滿足需求。

市場定義：

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

形式和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於MicrosoftExcel）
  • 流行病學資料（MS Excel，互動式工具）
  • 高層洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

提及公司

  • EpicentRx, Inc.
  • OncoZenge AB
  • MitoImmune Therapeutics

目錄

第1章 主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章 疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 依藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要療法 - 概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 值得關注的後期新興療法 - 概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期管道

第6章 未滿足的需求與目標產品分析

  • 主要未滿足需求及新興療法的未來成就
  • TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

簡介目錄

Global Oral Mucositis Market Outlook

Thelansis's "Global Oral Mucositis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oral Mucositis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Oral Mucositis Overview

Oral mucositis is a painful, often debilitating breakdown of the mouth's lining that develops as a side effect of chemotherapy, radiation, and stem cell transplantation, frequently forcing interruptions or dose reductions in the cancer treatment causing it and materially affecting nutrition, comfort, and quality of life. Despite decades of clinical attention, the condition still lacks a therapy that reliably prevents or resolves it, and drug development here has struggled to translate early promise into approved products, leaving supportive measures such as oral hygiene protocols, cooling techniques, protective coatings, and photobiomodulation as the practical backbone of care. Interest is now shifting toward the biological drivers of severity, including the oral microbiome's role in amplifying tissue damage, steering newer investigational approaches toward combination strategies that pair anti-inflammatory action with antimicrobial or tissue-healing mechanisms rather than a single target. For stakeholders, oral mucositis remains a persistent, high-need supportive-care category where expanding treatment volumes sustain demand, even as an effective therapy stays elusive.

Key Highlights

  • In Germany, diagnosed incident Oral Mucositis cases are projected to increase from 562,562 in 2025 to 602,105 by 2035.
  • Oral Mucositis is a common complication of chemotherapy and radiotherapy, significantly impacting patient quality of life and treatment adherence.
  • Severe cases may lead to treatment interruptions, increased infection risk, and higher healthcare costs.
  • Significant unmet need remains for therapies that effectively prevent and manage oral mucosal injury.

Market Overview

  • The Germany Oral Mucositis market is projected to grow from $55M in 2025 to $130M by 2035.
  • Market growth is driven by:
  • Increasing cancer incidence and use of intensive anticancer therapies
  • Growing adoption of supportive care and novel preventive treatments
  • Future growth will depend on therapies capable of preventing severe mucositis and improving treatment continuity.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Market Definition:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

  • EpicentRx, Inc.
  • OncoZenge AB
  • MitoImmune Therapeutics

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)